GlassScriptPhysician profile
James C Azurin
NPI 1932182649
$18,143.10
in general payments reported to CMS, 2019-2025
72 companies · $3,913 in 2025
The $3,913 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,084 · 2020: $2,085 · 2021: $1,771 · 2022: $730 · 2023: $2,434 · 2024: $3,127 · 2025: $3,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,473.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.21 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Teva Pharmaceuticals USA, INC. | $1,170.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $1,149.01 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $1,123.52 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Pfizer INC. | $858.40 | 2019-2025 | |
| Lundbeck LLC | $844.32 | 2019-2025 | Vyepti |
| Biogen, INC. | $764.34 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Amgen INC. | $628.99 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $615.85 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Novartis Pharmaceuticals Corporation | $587.78 | 2019-2025 | |
| Ucb, INC. | $545.68 | 2019-2025 | Rystiggo, Nayzilam, Fintepla |
| Neurocrine Biosciences, INC. | $509.50 | 2019-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $504.01 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $414.56 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $390.69 | 2021-2025 | Ultomiris, Soliris |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Azurin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.